Century Therapeutics Inc

NASDAQ IPSC

Data sourced from iex and EODHD
Download Data

Century Therapeutics Inc Income Statement 2015 - 2024

This table shows the Income Statement for Century Therapeutics Inc going from 2015 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2016-12-31 2015-12-31
Revenue
M 1 0 0 0 2 1 2 1 1 0 0 0 0 0 0 0 0 470 951
Cost of Revenue
M 3 4 2 2 2 3 - - - - - - - - - - - 468 889
Gross Profit
M -2 -3 -2 -2 0 -3 2 1 1 - - - - - - - - - -
Operating Expenses
M 29 27 34 33 32 30 34 33 38 - - - - - - - - - -
Selling, General, and Administrative Expenses (SG&A)
M 9 9 9 8 9 8 8 8 7 6 6 4 3 3 2 2 2 81 109
Research and Development (R&D) Expenses
M 20 22 23 23 25 26 26 24 31 22 20 19 15 12 11 8 8 9 11
Other Operating Expenses
M 0 -4 2 2 -2 -3 0 0 0 - - - - - - - - - -
Costs and Expenses
M 26 24 30 29 32 30 - - - - - - - - - - - - -
Operating Income
M -31 -31 -36 -35 -32 -33 -32 -31 -37 -28 -26 -23 -18 -15 -13 -16 -10 - -
Interest Expense
M 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 29 24
Non-operating Income/Expense
M 3 -10 -4 -4 2 2 1 0 0 -5 0 0 0 1 0 -5 0 - -
EBT
M -28 -40 -32 -32 -30 -32 -31 -31 -37 -28 -26 -23 -18 -16 -13 -15 -10 - -
Income Tax Provision
M 0 -1 1 1 1 0 0 0 0 0 0 0 0 1 0 - 0 - -
Income after Tax
M -28 -39 -33 -33 -31 -32 -31 -31 -38 -28 -26 -23 -19 -17 -13 - -10 - -
Non-Controlling Interest
M - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 0 - -
Net Income
M - - - -33 -31 -32 -31 -31 -38 -28 -26 -23 -18 - -13 -15 -10 - -
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 62,296,637.00 59,882,438.00 59,448,229.00 59,251,363.00 58,610,375.00 57,755,842.00 57,973,541.00 57,685,006.00 57,051,539.00 54,472,650.00 54,472,650.00 54,404,091.00 54,824,608.00 41,803,724.00 41,803,724.00 41,803,724.00 41,803,724.00 - -
EBITDA
M -28 -27 -28 -25 -30 -28 -28 -29 -36 -28 -25 -22 -17 -15 -13 -10 -9 - -
Depreciation and Amortization
M 3 4 3 3 2 5 4 2 1 1 1 1 1 1 0 0 0 - -
EBIT
M -31 -31 -31 -28 -32 -33 -32 -31 -37 -29 -26 -23 -18 -15 -13 -11 -10 - -
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% 0.00 2.16 -1.84 -2.94 -4.02 -0.10 -0.08 -0.06 -0.04 -0.15 -0.24 0.04 -1.86 -6.70 -0.81 - -3.31 - -
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 0 - -
Gross Profit Margin
% -277.31 -1,225.37 -1,107.43 -2,333.33 -26.16 -549.33 100.00 100.00 100.00 - - - - - - - - - -
Operating Income Margin
% -3,661.87 -11,424.25 -24,071.62 -35,431.31 -1,865.17 -6,392.71 -1,427.07 -2,245.77 -3,538.37 - - - - - - - - - -
Net Income Margin
% - - - -33,627.27 -1,817.67 -6,081.00 -1,382.60 -2,219.77 -3,545.65 - - - - - - - - - -
EBITDA Ratio
% -3,284.56 -10,098.88 -19,005.41 -25,001.01 -1,723.95 -5,469.10 -1,243.44 -2,080.80 -3,412.00 - - - - - - - - - -
EBIT Ratio
% -3,661.87 -11,424.25 -21,268.92 -28,267.68 -1,865.17 -6,392.71 -1,427.07 -2,245.77 -3,538.37 - - - - - - - - - -
EBT Ratio
% -3,281.99 -15,025.00 -21,708.11 -32,667.68 -1,747.44 -6,074.86 -1,381.47 -2,218.48 -3,544.14 - - - - - - - - - -

StockViz Staff

September 16, 2024

Any question? Send us an email